

Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model



Sonia Domingos-Pereira¹, Karthik Sathiyandan¹, Stefano La Rosa², Lenka Polák¹, Mathieu F. Chevalier¹, Paul Martel¹, Rim Hojeij¹, Laurent Derré¹, Jacques-Antoine Haefliger³, Patrice Jichlinski¹, and Denise Nardelli-Haefliger¹

Abstract

Preclinical data show that intravesical instillation of Ty21a/Vivotif, a commercial vaccine against typhoid fever, is an effective alternative option to standard Bacillus Calmette–Guérin (BCG) immunotherapy for non-muscle-invasive bladder cancer (NMIBC). Here, we characterized the inflammatory effects of Ty21a on the bladder and investigated the immune mechanisms underlying tumor regression toward the use of this bacterial vaccine in NMIBC patients. MB49 bladder tumor-bearing mice had significantly improved survival after intravesical instillations of Ty21a doses of 10^6 to 10^8 colony-forming units. By IHC and morphology, both BCG and Ty21a instillations were associated with bladder inflammation, which was decreased with the use of low, but effective doses of Ty21a. Flow-cytometry analysis showed a significant infiltration of T cells, natural killer (NK) cells, and myeloid cells,

compared with controls, after a single dose of Ty21a, whereas this was only observed after multiple doses of BCG. The induced myeloid cells were predominantly neutrophils and Ly6C⁺CD103⁺ dendritic cells (DC), the latter being significantly more numerous after instillation of Ty21a than BCG. *Ex vivo* infection of human leukocytes with Ty21a, but not BCG, similarly significantly increased DC frequency. CD4⁺ and CD8⁺ T cells, but not NK cells nor neutrophils, were required for effective bladder tumor regression upon Ty21a treatment. Thus, the generation of antitumor adaptive immunity was identified as a key process underlying Ty21a-mediated treatment efficacy. Altogether, these results demonstrate mechanisms behind intravesical Ty21a therapy and suggest its potential as a safe and effective treatment for NMIBC patients.

Introduction

Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively (1, 2). Approximately 75% of bladder cancers are diagnosed as non-muscle-invasive (3), and according to specific tumor stage and grade characteristics, intravesical immunotherapy with Bacillus Calmette–Guérin (BCG) is used to prevent recurrence and/or progression (4). However, BCG immunotherapy is associated with significant adverse events, mainly bladder irritation, general malaise, and fever, but also severe though rare complications (5). In addition, treatment failure may occur in 30% to 40% of cases (6), hence the necessity for alternatives. Along this line, we reported that the

attenuated *Salmonella enterica* serovar Typhi Ty21a live vaccine-strain against typhoid fever was effective at inducing regression of established bladder tumors using the immunocompetent orthotopic MB49 bladder cancer model (7), which closely mimic non-muscle invasive bladder cancer (NMIBC) in mice (8). Besides the excellent safety profile of the oral Ty21a vaccine Vivotif, as confirmed worldwide in more than 200 million vaccinees over the last 30 years (9), the absence of bacterial survival in the bladder (7) points to it as a viable candidate to test in NMIBC patients. Toward this goal, it is crucial to examine whether the local adverse events associated with BCG may also be induced by intravesical Ty21a. Here we characterized the inflammatory effects of Ty21a on the bladder, but also investigated the innate and/or adaptive immune mechanisms underlying tumor regression in the MB49 bladder cancer model. Using morphology, IHC, and flow cytometry, we comparatively characterized inflammation and immune cell infiltration in the bladder upon the different intravesical treatments and functionally determined key effector cells. Altogether, we highlighted mechanisms of intravesical Ty21a therapy that may have the potential for safe and efficient implementation in NMIBC patients.

¹Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ²Service of Clinical Pathology, Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ³Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Note: Supplementary data for this article are available at Cancer Immunology Research Online (<http://cancerimmunolres.aacrjournals.org/>).

S. Domingos-Pereira and K. Sathiyandan contributed equally to this work as first authors.

Corresponding Author: Denise Nardelli-Haefliger, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Bugnon 48, 1011 Lausanne, Switzerland. Phone: 4121-314-40-81; Fax: 4121-314-40-60; E-mail: dnardell@hospvd.ch

doi: 10.1158/2326-6066.CIR-18-0671

©2019 American Association for Cancer Research.

Materials and Methods

Mouse cells

The MB49 cell line, derived from a carcinogen-induced urothelial carcinoma in male C57Bl/6 mice in 1979 (8), was kindly provided in 2009 by Professor A. Loskog (Uppsala University, Sweden), amplified for 1 week (2 passages), and aliquots were

frozen. Luciferase-expressing (MB49-luc) and green fluorescent protein (GFP)-expressing (MB49-GFP) cells were generated by transfection with lentiviral vectors encoding for firefly luciferase and GFP, respectively (kindly provided by Prof. D. Trono, EPFL, Lausanne, Switzerland) of one MB49 aliquot after 1 passage. MB49-luc and MB49gfp were amplified during 1 week (2 passages), tested as free of *mycoplasma* and aliquots frozen. Further amplifications (2 passages) from the initial stock were performed in 2012 and 2018 to generate new aliquots. In all experiments, a new aliquot of cells is used within 10 days after thawing.

The MB49 orthotopic bladder tumor model

Seven- to 10-week-old female C57Bl/6 wild-type mice (Charles River) were used, and all experiments were performed in accordance with Swiss law and with approval of the Cantonal Veterinary Office of Canton de Vaud, Switzerland. Bladder tumors were established in deeply anesthetized mice that were urethral catheterized using Introcan 24Gx3/4 catheters (Braun). A 15-minute pretreatment with 100 μ L 22% ethanol was performed before instillation of 500,000 MB49-luc (or MB49-GFP) cells in a volume of 50 μ L. MB49-luc tumor growth was monitored by bioluminescence 15 minutes after intraperitoneal (i.p.) injection of D-luciferin (Promega, L8220, 150 μ g/g of body weight) in the Xenogen imaging system (Xenogen/IVIS Caliper Life Science, kindly provided by cellular imaging facility, CIF/UNIL, Lausanne, Switzerland). One hundred percent of the mice will develop bladder tumors. Bioluminescence monitoring of MB49-luc tumors is very efficient for assessing tumor establishment and growth during the first 3 weeks; however, uncontrolled loss of luminescence of the growing tumors can then often appear (10), requiring additional monitoring by palpation, hematuria, and overall health status of the mice, which were euthanized if they reached > 15% weight loss.

Ty21a and BCG bacteria preparation

Ty21a bacteria were prepared by resuspension of the lyophilized content of a Vivotif capsule (PaxVax) into 750 μ L of PBS, resulting in ca. 3×10^9 CFU/mL. BCG bacteria were prepared by resuspension of one vial of oncoTICE (Essex Chemie SA) in 1 mL of PBS, resulting in ca. 3×10^8 CFU/mL. Further dilutions were made in PBS as required to achieve the indicated bacteria numbers used in the experiments.

Intravesical treatments

Bacterial suspensions (50 μ L) were instilled by urethral catheterization, as described above. The retention time in the bladder was ca. 1 hour, until the mice awoke from the anesthesia and would spontaneously urinate. Classic treatment (Table 1) starts 1 day after intravesical tumor-cell instillation and is administered 4 times at weekly intervals (days 2, 9, 16, and 23). In a more stringent setting, a single intravesical treatment instillation was administered at day 2 (24 hours after intravesical tumor-cell instillation). Tumors can be detected by bioluminescence at day 5 and grow until days 9 to 12 at a similar rate, irrespective of instillation with PBS versus BCG or Ty21a.

Morphology and IHC

Three-micrometer paraffin-embedded hematoxylin–eosin-stained sections were used for morphologic evaluation of bladder specimens, including the urothelial mucosa, muscular, subserosa,

Table 1. Dose-dependent efficacy of intravesical treatments of MB49 bladder tumor-bearing mice

Treatments ^a	Surviving mice at day 70 (%)	Number of alive mice/initial total number	P values ^b
Ty21a 3×10^8 CFU ^c	80	16/20	0.0076
Ty21a 3×10^7 CFU	85	17/20	0.0023
Ty21a 3×10^6 CFU	90	9/10	0.0060
BCG 3×10^7 CFU	80	16/20	0.0076
BCG 3×10^6 CFU	70	7/10	0.1141
PBS	33.3	6/18	NA ^d

^aTreatments were instilled 1, 8, 15, and 22 days after tumor implantation.

^bP values after comparison with PBS treatment following a Fisher exact test.

^cCFU, colony-forming unit.

^dNA, not applicable.

and serosa layers. The inflammation was evaluated using an inflammatory scoring system as previously reported (11). Score 0: absence or minimal inflammation or epithelial changes. Score 1: mild inflammation within the lamina propria accompanied by mild chronic edema, hemorrhage, or urothelial changes, zonal fibrosis in lamina propria. Score 2: moderate inflammatory infiltrate in the lamina propria and focal extension of the inflammation into the muscularis propria, accompanied by moderate edema, hemorrhage, urothelial changes, and diffuse fibrosis in the lamina propria. Score 3: severe inflammation in the lamina propria and muscularis propria in association with other significant findings including urothelial ulceration, severe chronic edema, hemorrhage, and diffuse fibrosis. For IHC evaluation, paraffin sections of bladders were immunostained using the following primary antibodies: CD11b (Abcam ab133357), F4/80 (Caltag MF48000), and CD3 (Abcam ab5690), an avidin-biotinylated horseradish peroxidase complex (Vectastain Elite ABC Kit), and counterstained with hemalun.

Immunostaining and flow-cytometry analysis

Mice were sacrificed by CO₂ inhalation to collect the bladders. Single-cell suspensions were obtained by mincing in DL-dithiothreitol (Sigma, D9779) and digesting stepwise with 0.5 mg/mL thermolysin (Sigma, T7902) and 1 mg/mL collagenase/dispase (Roche, 11 097 113 01; ref. 12) or by single digestion step with 1 mg/mL collagenase/dispase and 0.1 mg/mL DNase I (Sigma-Aldrich, D2552) with 20% fetal calf serum (Gibco, 10270). Whole blood was collected in tubes containing heparin-Na 25000 I.E. (Braun, 1718711) from tail vein. Red blood cells were lysed using ammonium–chloride–potassium.

The recovered cells were stained and analyzed by flow cytometry. The following monoclonal antibodies (mAb) to mouse proteins were used: CD3-PE (17A2, 100206), CD3-PerCP/Cy5.5 (17A2, 100218), Ly6G-PE/Cy7 (1A8, 127618), CD11b-APC (M1/70, 101212), Ly6C-AF700 (HK1.4, 128024), Ly6C-APC/Cy7 (HK1.4, 128026), NK1.1-AF700 (PK136, 108730), CD4-AF700 (GK1.5, 100430), CD8-APC/Cy7 (53-6.7, 100714), F4/80-APC-Cy7 (BM8, 123118), CD103-Pcblue (2E7, 121418; BioLegend); CD4-eF450 (GK1.5, 48-0041-82), CD11c-PE (N418, 48-0041), CD11c-PE-eF610 (N418, 61-0014, CD45-PerCP/Cy5.5 (30-F11, 45-0451; eBioscience); CD8-PETXRD (53-6.7, 1550-10; Southern Biotech). Isotype controls were used for CD11c-PE-eF610 [Harmenia Hamster IgG-PE-ef610 (eBio 229 Arm, 61-4888-80) from eBioscience] and for F4/80-APC-Cy7 and CD8-APC/Cy7 [Rat IgG2a kappa-APC/Cy7 (RTK 2758, 400524) from BioLegend]. FMO was used for CD103-Pcblue determination.

Dead cells were excluded by a live/dead fixable aqua dead cell stain kit (L34957, Invitrogen, Thermo Fisher Scientific). Cell acquisition and analysis were performed using Gallios Flow Cytometer (Beckman Coulter) and FlowJo software (Tree Star), respectively.

In vitro infections of human leukocytes for DC analysis

Peripheral blood from healthy volunteers was obtained through the local Swiss blood bank. Fresh peripheral blood mononuclear cells (PBMCs) were purified by density gradient centrifugation and cryopreserved. PBMCs were infected with Ty21a or BCG at the indicated multiplicity of infection (MOI) for 1.5 hours at 37°C. Cells were washed and medium containing 50 µg/mL gentamycin was added. Following 24 hours of incubation at 37°C, cells were harvested and stained for DC identification by flow cytometry. The following mAbs to human proteins were used: CD11c-BV421 (Bu15, 337225), HLA-DR-PE/Cy7 (L243, 307616), and CD14-FITC (HCD14, 325604) from BioLegend; CD3-PE/AF610 (7D6, MHCD0322), CD19-PE/AF610 (SJ25C1, MHCD1922), and CD56-PE/TexasRed (MEM-188, MHCD5617) from Invitrogen. Cells were stained for 20 minutes at 4°C, and an amine reactive dye (aqua live/dead stain kit, from Life Technologies, L34957) was used for dead cell exclusion according to the manufacturer's instructions. Fc-receptor blocking reagent (Miltenyi Biotec, 130-059-901) was used to increase staining specificity. Sample acquisition was performed as described above.

In vivo immune cell depletion

The following mAbs from Bio X Cell were used for cell depletion: CD8 (2.43, BE 0061), CD4 (GK1.5, BE 0003), NK1.1

(PK136, BE 0036), Ly6G (1A8, BE 0075), Ly6C (Mons1, BE 0203), or rat IgG2a (2A3, Roche), or IgG2b (LTF2, BE 0090) as isotype controls. A first i.p. injection of 100 µg (anti-CD8), 200 µg (anti-CD4 or anti-Ly6G), 250 µg (anti-NK1.1), or 400 µg (anti-Ly6C), or isotype controls was given 2 days before tumor implantation. This was followed by i.p. injections every 3 to 5 days, for a period of ca. 40 days, using half of the first dose (except for anti-CD4 and anti-Ly6C that were injected at full dose).

Statistical analysis

Statistical analyses were performed using Prism 7.00 for Windows (GraphPad software). Single comparisons were performed using Student *t* test. Multiple comparisons were performed using one-way ANOVA and Dunnet post-test or adjusted log-rank test as indicated in the figure legends.

Results

Dosage range of effective intravesical Ty21a bladder tumor treatment

Using the mouse MB49 orthotopic bladder cancer model (13–15), we determined the dosage range of efficacy of the intravesical Ty21a and BCG treatments (Table 1). After four consecutive instillations (1 week apart, starting 1 day after tumor implantation; ref. 16), Ty21a induced a significantly higher mice survival (80%–90%), as compared with control PBS treatment using doses ranging from 3×10^6 to 3×10^8 CFU/dose (the maximal dose tested, corresponding to 1/10 of the content of the Vivotif capsule). Similar survival in mice was also obtained with BCG at 3×10^7 CFU/dose (the maximal dose tested, corresponding to 1/10 of the Oncotice vial),




Figure 1.

Bladder inflammation upon intravesical Ty21a or BCG instillations. Hematoxylin–eosin-stained, paraffin sections of bladders from mice ($n = 3-6$) euthanized 1 or 7 days after a single or four consecutive (once per week) intravesical instillations with PBS, BCG (3×10^7 or 3×10^6 CFU), or Ty21a (Ty, 3×10^7 or 3×10^6 CFU) were compared with naïve mice using an inflammatory score. Representative pictures of inflammatory scores of 0, 1, 2, and 3 are shown in **A**. Fibrosis (arrowhead), edema (star), and ulceration (arrow) are indicated; original magnification was 200 \times . Means \pm SEM of inflammatory scores in the groups of mice that received a single intravesical instillation (**B**) or 4 consecutive instillations (**C**) as indicated below the graphs, are shown. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$ following a one-way ANOVA and a Dunnet post-test for comparison with naïve mice.

whereas treatment with the lower BCG dose (3×10^6 CFU) no longer conferred significantly improved survival, compared with controls (Table 1). This shows that multiple intravesical Ty21a instillations can control tumor growth and increase survival in mice with doses as low as 3×10^6 CFU.

Characterization of bladder wall inflammation upon intravesical treatments

Intravesical bladder immunotherapy with BCG or Ty21a is associated with the induction of inflammatory cytokines (7, 17). Here, we show a morphologic analysis of treated bladders to characterize inflammatory features, including the presence of edema, fibrosis, and immune cell infiltration, as summarized by an inflammatory score (ref. 11; Fig. 1A). Single intravesical instillation with either BCG or Ty21a (3×10^7 CFU) induced significant inflammation in the bladder 24 hours later, which was considerably decreased after 7 days (Fig. 1B). Similar inflammation was induced 24 hours after the fourth consecutive instillation with either BCG or Ty21a; however, inflammation persisted for at least 3 weeks (Fig. 1C). When the lower dose (3×10^6 CFU) was used, inflammation was still present upon BCG administration, but not upon Ty21a treatment. These data show that bladder tissue inflammation can be reduced by using low, but still effective (Table 1), doses of Ty21a.

Characterization of immune cell infiltration in the bladder upon intravesical treatments

Infiltration of myeloid cells and T cells in the bladder upon Ty21a or BCG instillations was evaluated by IHC (Fig. 2A; Table 2). Myeloid cells (CD11b⁺), mainly of the granulocytic phenotype, were slightly increased within 24 hours following instillation of PBS alone and to a greater extent by BCG or Ty21a; however, within 7 days, myeloid/granulocytes represented again less than 10% of the bladder area similarly to the PBS-treated bladder. In contrast, following multiple BCG instillations (either 3×10^6 or 3×10^7 CFU/dose), a strong (10%–50% of the bladder area; Table 2) myeloid/granulocyte infiltration was maintained for at least 3 weeks. Macrophages (F4/80⁺) were only consistently observed after multiple doses of BCG, whereas T cells (CD3⁺) were increased by Ty21a at early time points (24 hours) and by BCG at later time points (3 weeks). Immune cell infiltration was further characterized and quantified by flow-cytometry (Fig. 2B and C; Supplementary Fig. S1A). The data show a significant infiltration in the bladder of T cells and natural killer (NK) cells 24 hours after a single Ty21a instillation, whereas myeloid cells were significantly induced by either Ty21a or BCG, as compared with PBS-treated and untreated mice (Fig. 2B). A significantly greater number of T cells was maintained for 1 week after Ty21a instillation (Fig. 2B, left), whereas NK cells and myeloid cells returned to the numbers measured in PBS-instilled or untreated mice (Fig. 2B, middle and right). A 10-fold higher dose of Ty21a (3×10^8 CFU) did not induce greater immune cell infiltration (Fig. 2B, dark green bars). After multiple instillations (Fig. 2C), there was a significant increase in T cell, NK, and myeloid cell numbers upon successive BCG instillations as compared with the first dose. In contrast, successive Ty21a doses did not further increase the number of myeloid cells and only to a lesser extent the number of T cells and NK cells (only significant after the third and fourth doses), as compared with the first dose (Fig. 2C). The myeloid cells induced after instillation were further phenotyped by flow cytometry (Supplementary Fig. S1B). They

consisted predominantly of Ly6G⁺ neutrophils (40%–60%), followed by Ly6C⁺ monocytes (15%–20%), dendritic cells (DC; 15%–30%), and fewer F4/80⁺ macrophages (3%–7%; Table 3), in agreement with the IHC data (Table 2). Although the proportion of neutrophils was significantly higher upon BCG administration than upon Ty21a treatment, the proportion of DCs was higher upon treatment with Ty21a than with BCG. Further analysis of DCs infiltrating the bladder upon instillation of Ty21a or BCG (Fig. 2D and E) showed that they were mainly Ly6C⁺CD103⁺CD11c⁺ DCs (Fig. 2D) in both type of intravesical instillations, but in significantly higher numbers upon treatment with Ty21a than BCG (Fig. 2E). These DCs thus shared markers of both inflammatory (Ly6C⁺; ref. 18) and cross-presenting (CD103⁺; ref. 19) DCs. Their presence in the bladder, together with the higher number of T cells (Fig. 2E), highlights the potential of Ty21a to promote antitumor T-cell responses locally.

In contrast to BCG, Ty21a infection of human PBMC increases DC frequency

As a surrogate for comparing the effects of BCG and Ty21a instillations on human bladder DC, we examined DC frequency upon *ex vivo* infection of human PBMCs. Data show that 24 hours after infection, the frequency of DCs (Lineage^{neg}CD11c⁺HLA-DR^{high}; Fig. 3A) was significantly increased by Ty21a, but not by BCG (both at an MOI = 0.5), as compared with medium alone (Fig. 3B). A significantly higher frequency of DCs was also obtained with Ty21a when high MOI (10) was used. In contrast, infection with BCG at MOI = 10 resulted in a significantly decreased DC frequency as compared with medium (Fig. 3B), suggesting a higher toxicity of BCG toward myeloid cells (see total CD11c⁺ cell frequency in Supplementary Fig. S2), possibly attributed to its greater persistence in PBMC as compared with Ty21a (7). Altogether, these data suggest that intravesical Ty21a may also promote DC infiltration in the human bladder, in contrast to BCG.

Functional characterization of effector cells involved in Ty21a bladder tumor treatment

We examined the presence of DCs in MB49 bladder tumors following intravesical treatments performed with BCG or Ty21a 1 day or 5 days after tumor instillation. At both time points, significantly higher numbers of CD103⁺Ly6C⁺CD11c⁺ DCs/mg of bladder tumor were obtained 1 day after intravesical Ty21a as compared with BCG (Fig. 4A), similar to the data obtained in the absence of tumor (Fig. 2E). To highlight the potential of CD103⁺Ly6C⁺CD11c⁺ DCs to present tumor antigen, we used MB49 cells expressing GFP and examined whether these DCs had engulfed GFP from the tumors. Compared with MB49-luc tumors, ca. 5% of CD103⁺Ly6C⁺CD11c⁺ DCs were GFP⁺ at day 6 in MB49-GFP tumors (Fig. 4B). Comparison between intravesical BCG and Ty21a treatments in this setting further confirmed that a significantly higher number of CD103⁺Ly6C⁺CD11c⁺ GFP⁺ DCs/mg of tumor was obtained after Ty21a than after BCG (Fig. 4C). This suggests that CD103⁺Ly6C⁺CD11c⁺ DCs may be key for the Ty21a treatment.

To functionally investigate the immune cells involved in the Ty21a-mediated tumor regression, we performed a single Ty21a intravesical instillation (3×10^7 CFU) 1 day after MB49 bladder tumor implantation, a treatment protocol that we previously showed to significantly increase mice survival (7). This allowed antibody-mediated immune cell depletion to be performed




Figure 2.

Immune cell infiltration upon intravesical Ty21a or BCG instillations. **A**, IHC characterization of the immune infiltrates upon intravesical instillations. T cells (CD3⁺, left image), macrophages (F4/80⁺, middle image), and myeloid cells (CD11b⁺) including mainly granulocytes (right image) are identified. **B** and **C**, Flow-cytometry analysis of immune cells recovered from bladders of naïve mice or from mice euthanized at the indicated time points after a single intravesical instillation with PBS, BCG (3×10^7 CFU), or Ty21a (Ty, 3×10^7 or 3×10^8 CFU, labeled as Ty10x; **B**) or 24 hours after each successive intravesical instillations (post 1, 2, 3, and 4; **C**). Individual values and mean \pm SEM numbers for CD3⁺ T cells, NK1.1⁺ NK cells, and CD11b⁺ myeloid cells are shown. **D** and **E**, Flow-cytometry characterization of DC recovered from bladder 24 hours after BCG and Ty21a (Ty, 3×10^7 CFU) intravesical instillation. Representative cytometry plots and histograms for DCs (Ly6C⁺ CD11c⁺ CD103⁺) and CD3⁺ T cells are shown for each treatment in **D**, and comparative analysis of myeloid and T-cell content (individual values and mean \pm SEM) is shown in **E**. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$ following a one-way ANOVA and a Dunnett post-test for comparison with naïve and to PBS in **B** or to post dose 1 in **C** or following a one-way ANOVA multiple comparison and Sidak post-test between BCG and Ty21a (**E**).

Domingos-Pereira et al.

Table 2. Immunohistochemical evaluation of immune infiltration in the bladder upon intravesical instillations

Intravesical instillations	Time post last instillation	Cd11b ⁺ myeloid cells ^a	F4/80 ⁺ macrophages	CD3 ⁺ T cells
None	NA ^b	+ ^c	0	+
1 × PBS	24 hours	++	0	+
	1 week	++	+	+
1 × Ty21a 3 × 10 ⁷ CFU	24 hours	++++	+	+ / ++
	1 week	++	0	+
1 × BCG 3 × 10 ⁷ CFU	24 hours	+++	0	+
	1 week	++	+	+
4 ^d × PBS	24 hours	++	+	+
	1 week	++	0	+
	3 weeks	+	0	+
4 × Ty21a 3 × 10 ⁷ CFU	24 hours	++++	+	++
	1 week	+++	0	+
	3 weeks	++	+	++
4 × BCG 3 × 10 ⁷ CFU	24 hours	+++	+	+
	1 week	+++	+	++
	3 weeks	+++	+	+++
4 × Ty21a 3 × 10 ⁶ CFU	24 hours	+++	+	+
	1 week	++	+	+
	3 weeks	++	0	+
4 × BCG 3 × 10 ⁶ CFU	24 hours	+++	+	+
	1 week	++	+	+
	3 weeks	+++	+	+ / ++

^aMyeloid cells included mainly granulocytic cells.^bNA, not applicable.^cArea of 2 mm² was examined, and reported score is a median value of all counted cases: +, 1%-5% of bladder area; ++, 5%-10% of bladder area; +++, 10%-50% of bladder area; +++++, >50% of bladder area; 0 = none observed.^dIntravesical instillations were performed at days 1, 8, 15, and 22.


without interfering with successive Ty21a treatments. Depletion of CD4⁺ T cells, CD8⁺ T cells, NK cells, and Ly6G⁺ neutrophils was highly effective and maintained for more than 1 month, as detected in the blood (Supplementary Fig. S3A). In contrast, our attempt to deplete CD103⁺Ly6C⁺CD11c⁺ DC with an Ly6C-depleting antibody only resulted in partial depletion (ca. 50%) of the Ly6C⁺ myeloid cells in blood (Supplementary Fig. S3B) and

Table 3. Proportion of different immune cell subtypes among myeloid cells upon intravesical instillation

	Neutrophil ^a (Ly6G ⁺)	Monocytes ^a (Ly6C ⁺ CD11c ⁻)	Macrophages ^a (F4/80 ⁺ Ly6C ⁺ CD11c ⁻)	DC ^a (CD11c ⁺)
Naïve ^d	3.4 ± 1.1	8.4 ± 0.6	11.3 ± 1.7	42.0 ± 3.1
PBS	40.1 ± 14.4	16.1 ± 4.4	6.5 ± 2.1	22.2 ± 6.7
BCG	61.9 ± 0.5	15.3 ± 0.2	2.8 ± 0.5	14.9 ± 0.3
Ty21a	44.1 ± 1.2 ^{****c}	19.5 ± 1.0	2.7 ± 0.3	26.5 ± 2.1 ^{**c}

^a% among myeloid cells (mean ± SEM) 24 hours after intravesical instillations.^bn = 3 mice/each group.^c**, P < 0.01; ****, P < 0.0001 following a one-way ANOVA and a Sidak multiple comparison test of BCG against Ty21a.

of the Ly6C⁺CD11c⁺ DCs in the bladder (Supplementary Fig. S3C). Tumor luminescence, as a surrogate for tumor volume, was not significantly different 10 days after tumor implantation in the different treatment groups, whereas 1 week later, significantly larger tumors were found in CD4⁻, CD8⁻, and Ly6C-depleted Ty21a-treated mice compared with mice receiving intravesical Ty21a with isotype control antibodies (Fig. 4D). In contrast, neutrophil- or NK-depleted Ty21a-treated tumors were similar to those in control Ty21a-treated mice, suggesting that neutrophils and NK cells are not necessary for an effective Ty21a treatment. Indeed, mouse survival was not affected by the long-term depletion of neutrophils and NK cells (35–40 days) after intravesical Ty21a treatment (80%–90% survival; Fig. 4E). In contrast, CD4⁺ or CD8⁺ T-cell depletion rapidly decreased mouse survival, and all mice were euthanized before day 40 (Fig. 4E), demonstrating that these T cells were essential immune cells for Ty21a treatment efficacy. The survival of the Ly6C⁺-depleted group was not significantly affected, with only 2 of 10 mice dying at earlier time points than the control group (Fig. 4E). This suggests that the partial depletion of CD103⁺Ly6C⁺CD11c⁺ DCs was not sufficient for long-term interference with the Ty21a treatment. Altogether, these data demonstrate the requirement for T cells (CD4⁺ and CD8⁺) and suggest the importance of CD103⁺Ly6C⁺CD11c⁺ DCs for the intravesical Ty21a treatment

**Figure 3.**

DC frequency upon Ty21a or BCG infection of human PBMC. PBMCs were cultured for 24 hours alone or after BCG or Ty21a infection (Ty, MOI = 0.5 and MOI = 10). **A**, Representative flow-cytometry plots showing the gating strategy for the identification of dendritic cells (DC). After gating on live cells, DCs were defined as lineage^{neg}CD11c⁺HLA-DR^{high} (with lineage including CD3, CD19, CD56, and subsequently, CD14). **B**, DC frequencies (individual values and mean ± SEM) among live cells are shown for each indicated conditions. One-way ANOVA for paired values followed by Tukey post-test for multiple comparison: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.




Figure 4.

Key effector cells involved in intravesical Ty21a bladder tumor treatment. **A**, Comparative analysis of CD103⁺Ly6C⁺CD11c⁺ DC content in bladder tumor instilled with BCG or Ty21a (Ty) one day (D1) or 5 days (D5) after MB49 instillation. Individual numbers and mean of CD103⁺Ly6C⁺CD11c⁺ DCs/mg of tumor recovered 1 day after BCG or Ty21a (Ty) instillation are indicated. **B**, Representative cytometry plot of GFP⁺ cells among CD103⁺Ly6C⁺CD11c⁺ DCs in MB49-GFP tumors as compared with MB49-luc tumors. **C**, Comparative analysis of CD103⁺Ly6C⁺CD11c⁺GFP⁺ DC content in bladder tumor instilled with BCG or Ty21a 5 days after MB49-GFP instillation. Individual numbers and mean of CD103⁺Ly6C⁺CD11c⁺GFP⁺ DCs/mg of tumor recovered 1 day after BCG or Ty21a (Ty) instillation are indicated. Groups in **A** and **C** were compared with a Student *t* test. **D** and **E**, Groups of mice receiving a single intravesical Ty21a instillation (3×10^7 CFU) 1 day after bladder tumor implantation, as well as depleting antibodies (anti-Ly6C, $n = 10$; anti-Ly6G, $n = 8$; anti-NK cells, $n = 8$; anti-CD4, $n = 8$; and anti-CD8, $n = 8$), or an isotype control ($n = 26$), were compared. **D**, Individual and mean (horizontal bars) bladder tumor bioluminescences of the indicated groups of mice at days 10 and 17. **E**, Survival of the indicated groups of mice over time. The treatment groups were compared with the isotype group with a one-way ANOVA with Dunnett post-test (**D**) or an adjusted log-rank test (**E**). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

of bladder tumors, whereas, in contrast to BCG (17), neutrophils and NK cells are not necessary.

Discussion

Our data show that significantly improved survival of MB49 bladder tumor-bearing mice could be achieved by intravesical instillations of Ty21a at doses that induce only low inflammation in the bladder. With a single instillation, Ty21a induced significant infiltration of T cells and DCs in the bladder at numbers that required multiple instillations with BCG. In contrast to BCG, for which mechanisms of action involve induction of both innate (mainly neutrophils and NK cells) and adaptive immune responses (17), the therapeutic effect of Ty21a relied on the presence of T cells and DC, but not of neutrophils and NK cells.

Our results also indicate that a particular type of DC expressing Ly6C, CD11c, and CD103 infiltrated the bladder and the MB49 bladder tumor upon Ty21a or BCG instillation. Ty21a instillation induced ca. 4-fold more of these DCs in the bladder than BCG. Similar Ly6C⁺ DCs were reported to differentiate from monocytic precursors upon inflammatory signals activating p53 within tumors undergoing immunogenic chemotherapies (20). Whether Ty21a may use a similar process to promote such an immunogenic microenvironment within the treated tumor deserves further investigation. Experiments with human PBMC further con-

firmed an increased DC frequency upon Ty21a infection, in contrast to BCG. In the context of antituberculosis vaccines, the relatively poor immunogenicity of BCG was previously associated with DC impairments, such as a poor maturation capacity (21, 22). The presence of DCs able to efficiently cross-present tumor antigen for activating antitumor T-cell immunity is crucial for an effective immunotherapy (23). In the absence of a specific tumor antigen, we could not assess the cross-presenting potential of the Ly6C⁺CD11c⁺CD103⁺ DCs but demonstrated their ability to engulf tumor antigen (GFP). It was previously reported that *Salmonella enterica* serovar Typhi can induce maturation of human DC capable of cross-presenting bacterial antigen and priming Typhi-specific CD8⁺ T cells (24). Given that Ty21a can rapidly induce urothelial tumor-cell death (7), this in combination with Ty21a-induced DCs may enable efficient cross-presentation of the released tumor antigens and activation of antitumor T cells either locally and/or in the draining lymph nodes. This process may explain why a single intravesical instillation of Ty21a is more efficient than BCG to induce regression of established bladder tumors and improve survival of treated mice (7).

Here, we present a thorough analysis of the inflammatory effects of single and successive intravesical instillations of BCG on morphology and immune infiltration in the bladder of mice. Our analysis is in line with previously reported data from NMIBC patients undergoing intravesical BCG immunotherapy, which

resulted in augmented immune responses, including increased cytokine concentrations and immune cells in the urine upon successive BCG instillations (25–27). In contrast, a single Ty21a instillation was sufficient to induce DCs and T cells capable of controlling tumor growth. Successive instillation of Ty21a, compared with BCG, did not result in a similar profile of enhanced innate immune cell infiltration and inflammation of the mouse bladder, particularly when the lower doses were used. Repeated exposure to lipopolysaccharide of gram-negative bacteria was shown to transiently silence inflammatory cytokines to prevent excessive inflammation (28, 29), which may partly explain our finding.

Immunotherapy of NMIBC with BCG is multifactorial, relies on an intact immune system, as the inflammatory response is crucial, with neutrophils playing a primary role (14). This overt inflammation, however, often leads to adverse events that can greatly reduce the patient's compliance. Although attempts to reduce the dose of BCG to one third (30) or one half (31) resulted in decreased toxicity, full efficacy could not be guaranteed, and the standard BCG regimen is still recommended (32).

The finding that Ty21a-mediated immunotherapy can operate in the absence of NK cells, neutrophils, and overt inflammation therefore holds promise for the implementation of this type of intravesical treatment in NMIBC patients, and a phase I trial is currently recruiting patients in our hospital (NCT 03421236: IVES Ty21a).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012;62:10–29.
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* 2013;49:1374–403.
- Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. *Eur Urol* 2013;64:639–53.
- Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. *Eur Urol* 2011;59:997–1008.
- Contero P, Bohlé A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, et al. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. *Eur Urol* 2010;57:410–29.
- Yates DR, Roupert M. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. *World J Urol* 2011;29:415–22.
- Domingos-Pereira S, Cesson V, Chevalier MF, Derre L, Jichlinski P, Nardelli-Haeffliger D. Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. *Oncoimmunology* 2017;6:e1265720.
- Summerhayes IC, Franks LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. *J Natl Cancer Inst* 1979; 62:1017–23.
- Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A, et al. Vaccines against typhoid fever. *Vaccine* 2006;24:3804–11.
- Jurczok A, Fornara P, Soling A. Bioluminescence imaging to monitor bladder cancer cell adhesion in vivo: a new approach to optimize a syngeneic, orthotopic, murine bladder cancer model. *BJU Int* 2008;101: 120–4.
- Lv YS, Yao YS, Rong L, Lin ME, Deng BH, Xie Y, et al. Intravesical hyaluronidase causes chronic cystitis in a rat model: a potential model of bladder pain syndrome/interstitial cystitis. *Int J Urol* 2014;21:601–7.
- Revaz V, Debonneville A, Bobst M, Nardelli-Haeffliger D. Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR. *Clin Vaccine Immunol* 2008;15: 757–64.
- Günther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). *Cancer Res* 1999;59:2834–7.
- Suttman H, Riemensberger J, Bentien G, Schmaltz D, Stöckle M, Jocham D, et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. *Cancer Res* 2006;16:8250–7.
- Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmstrom PU, Totterman TH. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. *Lab Anim* 2005;39:384–93.
- Mangsbo SM, Ninalga C, Essand M, Loskog A, Totterman TH. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. *J Immunother* 2008;31:34–42.
- Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer—a current perspective. *Nat Rev Urol* 2014; 11:153–62.
- Segura E, Amigorena S. Inflammatory dendritic cells in mice and humans. *Trends Immunol* 2013;34:440–5.
- Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. *Nat Rev Immunol* 2012;12:557–69.
- Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, et al. Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c(+)CD103(+) monocytic antigen-presenting cells in tumors. *Immunity* 2018;48:91–106e6.
- Moliva JL, Turner J, Torrelles JB. Immune responses to Bacillus Calmette-Guérin vaccination: why do they fail to protect against mycobacterium tuberculosis? *Front Immunol* 2017;8:407.
- Bizzell E, Sia JK, Quezada M, Enriquez A, Georgieva M, Rengarajan J. Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T cell responses. *J Leukoc Biol* 2018;103:739–48.

Authors' Contributions

Conception and design: S. Domingos-Pereira, J.A. Haefliger, D. Nardelli-Haeffliger

Development of methodology: S. Domingos-Pereira, K. Sathiyandan, P. Martel, L. Derré, J.A. Haefliger

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Domingos-Pereira, K. Sathiyandan, L. Polák, M.F. Chevalier, P. Martel, R. Hojeij, D. Nardelli-Haeffliger

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Domingos-Pereira, K. Sathiyandan, S. La Rosa, L. Polák, M.F. Chevalier, P. Martel, L. Derré, D. Nardelli-Haeffliger

Writing, review, and/or revision of the manuscript: S. Domingos-Pereira, K. Sathiyandan, S. La Rosa, L. Polák, M.F. Chevalier, L. Derré, J.A. Haefliger, D. Nardelli-Haeffliger

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Domingos-Pereira, S. La Rosa, J.A. Haefliger

Study supervision: J.A. Haefliger, P. Jichlinski, D. Nardelli-Haeffliger

Acknowledgments

We thank the mouse pathology facility of the UNIL/CHUV for paraffin section and IHC staining. The study was funded by Swiss National Funds (#32153201 and #CRI13 160742 to D. Nardelli-Haeffliger); Swiss Cancer League #2808-08-2011 and KFS 4103022017 to D. Nardelli-Haeffliger and KFS 3796022016 to J.A. Haefliger; and InnoSTEP grant to D. Nardelli-Haeffliger.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 24, 2018; revised November 28, 2018; accepted January 25, 2019; published first January 29, 2019.

23. Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. *Immunity* 2016;44:924–38.
24. Salerno-Goncalves R, Szein MB. Priming of *Salmonella enterica* serovar typhi-specific CD8(+) T cells by suicide dendritic cell cross-presentation in humans. *PLoS One* 2009;4:e5879.
25. Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, et al. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus Calmette-Guerin therapy in patients with superficial bladder cancer. *J Urol* 2009;181:1571–80.
26. Pieraerts C, Martin V, Jichlinski P, Nardelli-Haeffiger D, Derre L. Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients. *Oncoimmunology* 2012;1:694–8.
27. Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. *J Clin Invest* 2017;127:2916–29.
28. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. *Nature* 2007;447:972–8.
29. Seeley JJ, Ghosh S. Molecular mechanisms of innate memory and tolerance to LPS. *J Leukoc Biol* 2017;101:107–19.
30. Martínez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical Bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. *BJU Int* 2002;89:671–80.
31. Yokomizo A, Kanimoto Y, Okamura T, Ozono S, Koga H, Iwamura M, et al. Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Guerin instillation therapy for nonmuscle invasive bladder cancer. *J Urol* 2016;195:41–6.
32. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. *Eur Urol* 2017;71:447–61.

Cancer Immunology Research

Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell–Mediated Tumor Regression in the MB49 Bladder Cancer Model

Sonia Domingos-Pereira, Karthik Sathiyandan, Stefano La Rosa, et al.

Cancer Immunol Res 2019;7:621-629. Published OnlineFirst January 29, 2019.

Updated version Access the most recent version of this article at:
doi:[10.1158/2326-6066.CIR-18-0671](https://doi.org/10.1158/2326-6066.CIR-18-0671)

Supplementary Material Access the most recent supplemental material at:
<http://cancerimmunolres.aacrjournals.org/content/suppl/2019/01/29/2326-6066.CIR-18-0671.DC1>

Cited articles This article cites 32 articles, 2 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/7/4/621.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/7/4/621>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.